Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity
| Autor: | Mehmet Tosun, Ozlem Kar Kurt, Fahrettin Talay, Aytekin Alcelik, Mehmet Fatih Özlü, Zehra Yasar, Aysel Kargi, Serkan Öztürk |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
medicine.medical_specialty Pathology Pregnancy-associated plasma protein A Immunology Comorbidity 030204 cardiovascular system & hematology Severity of Illness Index 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Pregnancy Internal medicine medicine Immunology and Allergy Humans Pregnancy-Associated Plasma Protein-A Lung cancer Asthma COPD business.industry medicine.disease Rheumatology respiratory tract diseases Pulmonary embolism 030228 respiratory system Cardiovascular Diseases Case-Control Studies Population study Increased inflammatory response Female business Biomarkers |
| Zdroj: | Inflammation. 39(3) |
| ISSN: | 1573-2576 |
| Popis: | Chronic obstructive pulmonary disease (COPD) represents a systemic disorder characterized by chronic airflow limitation and an increased inflammatory response of the airways. Comorbidities are frequent in COPD and it is crucial to predict these in early stage for adequate management of COPD. Recent studies have reported that elevated levels of pregnancy-associated plasma protein-A (PAPP-A), a zinc-binding metalloproteinase, detected in patients with asthma, lung cancer, and pulmonary embolism and independently associated with cardiovascular events. We aimed to assess serum PAPP-A levels in COPD and the associations between disease severity. The study population consisted of 75 COPD patients and 35 healthy subjects as a control group. PAPP-A levels were measured by using ultrasensitive enzyme-linked immunosorbent assay. Elevated levels of PAPP-A were observed in patients with COPD on comparison with the controls (p = 0.000). The levels in stage 1 (34.73 ± 22.97) and stage 2 (48.29 ± 53.35) were significantly higher than stage 3 (20.58 ± 22.98) and stage 4 (27.36 ± 21.46) (p = 0.049). Increased PAPP-A levels may be a useful marker in management of COPD that seeks to prevent the development of comorbidities such as adverse cardiovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink